Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 12, 2022
St. Gallen, Switzerland, 12 May 2022 – CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to...
-
Apr 28, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients First launches in Europe...
-
Apr 26, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Dividend of CHF 2.00 approved All Board members re-elected...
-
Apr 4, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure patients while on...
-
Mar 28, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 28 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...
-
Mar 23, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 23 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...
-
Mar 8, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 8 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...
-
Mar 3, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 3 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...
-
Feb 28, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of...
-
Feb 17, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Net sales up 4.0% and EBITDA up 6.6% at constant exchange rates (CER) a result of profitable growth in net sales combined with diligent cost containment...